Dovato vs Mavyret
A side-by-side look at two antiviral medications advertised on TV. Informational only — not medical advice.
Maintained by TVPills Editorial Team · Site updated November 4, 2026 (not a product-label review)
| Attribute | US Dovato | US Mavyret |
|---|---|---|
| Generic name | dolutegravir/lamivudine Unverified catalogue summary (Generic name) for Dovato in US; not checked against current local product information. | glecaprevir/pibrentasvir Unverified catalogue summary (Generic name) for Mavyret in US; not checked against current local product information. |
| Drug class | See official local label Unverified catalogue summary (Drug class) for Dovato in US; not checked against current local product information. | See official local label Unverified catalogue summary (Drug class) for Mavyret in US; not checked against current local product information. |
| Treats | HIV-1 infection Unverified catalogue summary (Treats) for Dovato in US; not checked against current local product information. | Hepatitis C Unverified catalogue summary (Treats) for Mavyret in US; not checked against current local product information. |
| Category | Antiviral Unverified catalogue summary (Category) for Dovato in US; not checked against current local product information. | Antiviral Unverified catalogue summary (Category) for Mavyret in US; not checked against current local product information. |
| Manufacturer | ViiV Healthcare Unverified catalogue summary (Manufacturer) for Dovato in US; not checked against current local product information. | AbbVie Unverified catalogue summary (Manufacturer) for Mavyret in US; not checked against current local product information. |
| Year approved | — Unverified catalogue summary (Year approved) for Dovato in US; not checked against current local product information. | — Unverified catalogue summary (Year approved) for Mavyret in US; not checked against current local product information. |
| Catalogue warning level | Safety summary withheld — check official label Unverified catalogue summary (Catalogue warning level) for Dovato in US; not checked against current local product information. | Safety summary withheld — check official label Unverified catalogue summary (Catalogue warning level) for Mavyret in US; not checked against current local product information. |
| Est. TV ad spend | $95M | $80M |
| Side effects and serious risks | — Unverified catalogue summary (Side effects and serious risks) for Dovato in US; not checked against current local product information. | — Unverified catalogue summary (Side effects and serious risks) for Mavyret in US; not checked against current local product information. |
Sources and editorial standards
Use the current DailyMed labels to verify approved uses, boxed warnings, and side effects for each medication. Label results can differ by product, strength, and formulation.
Page updated November 4, 2026; the linked resources have not necessarily been reviewed on this date.
Frequently asked questions
Is Dovato or Mavyret better?
This directory does not compare clinical effectiveness or safety. Listing Dovato and Mavyret together does not establish shared approved indications, equivalence or suitability as substitutes. Consult the correct local labels and your prescriber.
What's the difference between Dovato and Mavyret?
The table shows catalogue identification and estimated advertising information for Dovato and Mavyret, not a verified medical comparison. Medical descriptions, mechanisms and safety summaries are withheld.
Which one spends more on TV ads?
Dovato has the larger estimated TV advertising budget of the two.